A clinical review of viral hepatitis. 2019

Michelle Loader, and Rudolph Moravek, and Sarah E Witowski, and Lynette M Driscoll
At the University of Colorado School of Medicine in Aurora, Colo., Michelle Loader is a senior instructor in the Department of Medicine, Division of Hospital Gastroenterology and Hepatology; Rudolph Moravek and Sarah E. Witowski are instructors in the Department of Medicine, Division of Hospital Medicine; and Lynette M. Driscoll is an instructor in the Department of Surgery, Division of Transplant Surgery. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Viral hepatitis remains a significant public health problem in the United States, despite advances in antiviral therapy and effective vaccines. According to the CDC, about 20,000 deaths each year are attributed to viral hepatitis, and 5 million people are chronically infected and at risk for serious liver disease and hepatocellular cancer. This article reviews the three most common causes of viral hepatitis, screening guidelines, clinical features, medical management, approaches for primary prevention, and the natural history of untreated disease.

UI MeSH Term Description Entries
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D006525 Hepatitis, Viral, Human INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D). Viral Hepatitis, Human,Human Viral Hepatitides,Human Viral Hepatitis,Viral Hepatitides, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.

Related Publications

Michelle Loader, and Rudolph Moravek, and Sarah E Witowski, and Lynette M Driscoll
June 1982, The American journal of gastroenterology,
Michelle Loader, and Rudolph Moravek, and Sarah E Witowski, and Lynette M Driscoll
October 1995, Optometry and vision science : official publication of the American Academy of Optometry,
Michelle Loader, and Rudolph Moravek, and Sarah E Witowski, and Lynette M Driscoll
December 1977, Australian dental journal,
Michelle Loader, and Rudolph Moravek, and Sarah E Witowski, and Lynette M Driscoll
August 1975, JPMA. The Journal of the Pakistan Medical Association,
Michelle Loader, and Rudolph Moravek, and Sarah E Witowski, and Lynette M Driscoll
December 2015, Nihon rinsho. Japanese journal of clinical medicine,
Michelle Loader, and Rudolph Moravek, and Sarah E Witowski, and Lynette M Driscoll
December 1986, Virginia medical,
Michelle Loader, and Rudolph Moravek, and Sarah E Witowski, and Lynette M Driscoll
September 1975, JPMA. The Journal of the Pakistan Medical Association,
Michelle Loader, and Rudolph Moravek, and Sarah E Witowski, and Lynette M Driscoll
January 1973, The Journal of the Egyptian Public Health Association,
Michelle Loader, and Rudolph Moravek, and Sarah E Witowski, and Lynette M Driscoll
November 1968, Laboratory investigation; a journal of technical methods and pathology,
Michelle Loader, and Rudolph Moravek, and Sarah E Witowski, and Lynette M Driscoll
July 1986, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
Copied contents to your clipboard!